NEWS ALERT! 📢 We are excited to announce the completion of a €17 million ($18.5 million) Series A first close to advance our differentiated HDAC6 inhibitor pipeline to the clinic and support expansion of our R&D and management team. This funding round is led by Asabys Partners, with the participation of Eli Lilly and Company and the US CMT Research Foundation, alongside continued support from our historical investors PMV, AdBio partners, V-Bio Ventures, VIB and GEMMA FRISIUS - FONDS K.U.LEUVEN. As part of this milestone, we welcome Clara Campàs Moya, Managing Partner and co-founder of Asabys Partners, to the Augustine Board of Director, and announce the appointment of Gerhard Koenig as executive Chairman. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program! To learn more, read the full press release here: https://lnkd.in/eVtvQUdv #AugustineTx #SeriesA #CMT
Bravo!
Congrats!
Congrats! Result of hard work
Congratulations! Keep growing!
Congratulations to the whole team !
Great news. Congrats to the team!
Congratulations Frederik Rombouts & team Augustine Therapeutics
Well done!👍
Bravo Sylvain!
Partner at V-Bio Ventures
3moWonderful news, it was great witnessing this from up close. Welcome to Asabys Partners, Eli Lilly and Company and CMT Research Foundation.